Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CBX7 | O95931 | 1/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.42 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.42 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610978 | 0.93 | L3MBTL3 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL8150715 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL23712050 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2HRH3 | |
| SCHEMBL27991280 | 0.84 | L3MBTL3 (0.58) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL4550274 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL4315788 | 0.82 | L3MBTL3 (0.57) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL3938492 | 0.82 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1 | |
| SCHEMBL13207179 | 0.82 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1EPHX2 | |
| SCHEMBL5779438 | 0.81 | L3MBTL3 (0.55) | SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E | |
| SCHEMBL5209377 | 0.81 | L3MBTL3 (0.43) | SMN1; SMN2L3MBTL3L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020036437-A1 | SUBSTITUTED HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASES WHICH CONTAINS SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2020-02-20 | — | — | WO | disclosed |
| EP-3604304-A1 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018174650-A9 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | 재단법인 대구경북첨단의료산업진흥재단 | 2020-01-02 | — | — | WO | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20090042883-A1 | ANTITUMOR AGENT | KYOWA HAKKOKOGYO CO. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042883-A1 | ANTITUMOR AGENT | KYOWA HAKKOKOGYO CO. (JP) | 2009-02-12 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1852112-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | SMN1; SMN2 4682/4885L3MBTL3 1894/4885L3MBTL1 1050/4885 |
| US-20090042883-A1 | ANTITUMOR AGENT | MCL1, HDAC7, TP53 | SMN1; SMN2 3714/4885L3MBTL3 671/4885L3MBTL1 462/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SMN1; SMN2 4331/4885L3MBTL3 4302/4885L3MBTL1 4204/4885 |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | SMN1; SMN2 4264/4885L3MBTL3 941/4885L3MBTL1 1616/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | SMN1; SMN2 1221/4885L3MBTL3 4069/4885L3MBTL1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.